GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synageva BioPharma Corp (FRA:TMS1) » Definitions » Cyclically Adjusted Book per Share

Synageva BioPharma (FRA:TMS1) Cyclically Adjusted Book per Share : €0.00 (As of Mar. 2015)


View and export this data going back to . Start your Free Trial

What is Synageva BioPharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Synageva BioPharma's adjusted book value per share for the three months ended in Mar. 2015 was €18.357. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Synageva BioPharma's current stock price is €211.31. Synageva BioPharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2015 was €0.00. Synageva BioPharma's Cyclically Adjusted PB Ratio of today is .


Synageva BioPharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Synageva BioPharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synageva BioPharma Cyclically Adjusted Book per Share Chart

Synageva BioPharma Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synageva BioPharma Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synageva BioPharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Synageva BioPharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synageva BioPharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synageva BioPharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Synageva BioPharma's Cyclically Adjusted PB Ratio falls into.



Synageva BioPharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Synageva BioPharma's adjusted Book Value per Share data for the three months ended in Mar. 2015 was:

Adj_Book= Book Value per Share /CPI of Mar. 2015 (Change)*Current CPI (Mar. 2015)
=18.357/99.6211*99.6211
=18.357

Current CPI (Mar. 2015) = 99.6211.

Synageva BioPharma Quarterly Data

Book Value per Share CPI Adj_Book
200506 4.257 82.062 5.168
200509 3.654 83.876 4.340
200512 4.657 83.032 5.587
200603 4.760 84.298 5.625
200606 4.793 85.606 5.578
200609 5.591 85.606 6.506
200612 6.460 85.142 7.559
200703 8.037 86.640 9.241
200706 8.856 87.906 10.036
200709 9.549 87.964 10.814
200712 10.383 88.616 11.672
200803 10.179 90.090 11.256
200806 5.461 92.320 5.893
200809 6.475 92.307 6.988
200812 3.488 88.697 3.918
200903 4.045 89.744 4.490
200906 4.042 91.003 4.425
200909 4.154 91.120 4.542
200912 5.300 91.111 5.795
201003 5.900 91.821 6.401
201006 6.840 91.962 7.410
201009 9.215 92.162 9.961
201012 -13.579 92.474 -14.628
201103 8.854 94.283 9.355
201106 8.748 95.235 9.151
201109 9.196 95.727 9.570
201112 3.201 95.213 3.349
201203 5.424 96.783 5.583
201206 5.334 96.819 5.488
201209 7.764 97.633 7.922
201212 7.169 96.871 7.373
201303 9.385 98.209 9.520
201306 8.614 98.518 8.710
201309 11.135 98.790 11.229
201312 10.207 98.326 10.341
201403 13.179 99.695 13.169
201406 12.443 100.560 12.327
201409 12.147 100.428 12.049
201412 11.501 99.070 11.565
201503 18.357 99.621 18.357

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Synageva BioPharma  (FRA:TMS1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Synageva BioPharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Synageva BioPharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Synageva BioPharma (FRA:TMS1) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.

Synageva BioPharma (FRA:TMS1) Headlines

No Headlines